drugset / Trial / NCT00002775

Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

NCT00002775

Phase 1/2 Unknown 37 enrolled Herbert Irving Comprehensive Cancer Center
Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining docetaxel and estramustine in treating patients who have metastatic prostate cancer.

Timeline

Start
1998-02
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule Intravenous
Subject estramustine Other / unclassified Oral

Indications